An Open-Label, Pilot Study of Samarium - Sm 153 Lexidronam (Quadramet) in Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Oct 2016
At a glance
- Drugs Samarium-153-SM-lexidronam (Primary) ; Pamidronic acid; Zoledronic acid
- Indications Bone metastases; Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 10 Oct 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
- 11 Jan 2016 Planned primary completion date changed from 1 Sep 2015 to 1 May 2016 as reported by ClinicalTrials.gov.
- 31 Mar 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015, as reported by ClinicalTrials.gov.